Abstract:Interest is increasing in the use of different liquid chromatography techniques coupled online to mass spectrometry for the quantification of platinum anticancer drugs in human plasma to inform cancer chemotherapy. We developed, validated and studied the application of a method for quantification of intact oxaliplatin in human plasma using ultra high performance liquid chromatography hyphenated to inductively coupled plasma mass spectrometry (UHPLC-ICP-MS). Plasma samples were processed instantly after collection from patients to preserve oxaliplatin speciation by methanol-deproteinization, and storage of diluted supernatants (plasma:methanol 1:2 v/v) at -80 °C. UHPLC separation of intact oxaliplatin and internal standard (carboplatin) was achieved using a C18 column and linear gradient mobile phase (Mobile phase A: water-methanol (97:3 v/v), 0.075 mM sodium dodecyl sulfate, 9.79 nM thallium adjusted to pH 2.5 with trifluoromethanesulfonic acid; Mobile phase B: 100 % methanol (v/v)) with ICP-MS detection to monitor platinum and thallium at m/z 195 and 205, respectively. The limit of quantification was 50 nM in methanol-deproteinized diluted plasma (1:2 v/v). Linearity was established for calibration standards ranging from 50 to 500 nM made in methanol-deproteinized diluted plasma (1:2 v/v), and for dilution of higher concentration samples in blank matrix containing internal standard (final dilution 1:29 v/v). Intra-day and inter-day accuracy ranged from 96.8 to 103 % of nominal concentration and precision from 0.62 to 2.49 % coefficient of variation. Recovery was complete and a matrix effect confirmed the requirement for matrix-matched standards. Intact oxaliplatin was stable during storage for at least 473 days, and during analysis, in methanol-deproteinized diluted plasma (1:2 v/v). The method was applied to determining the plasma concentrations of intact oxaliplatin in patients undergoing cancer chemotherapy, and studies of oxaliplatin degradation in vitro. This improved method based on UHPLC-ICP-MS will allow more specific, efficient and reliable quantification of intact oxaliplatin in human plasma.

Application Of High Performance Capillary Electrophoresis Tandem Mass Spectrometry To The Investigation On The Stability Of Novel Anticancer Platinum Complex In Solution

Application of HPLC-ESI-MS/MS to the Determination of a Novel Antitumour Platinum Complex

Delivery of Platinum (II) Drugs with Bulky Ligands in Trans-Geometry for Overcoming Cisplatin Drug Resistance.

Investigation on Pharmacokinetics, Tissue Distribution and Excretion of a Novel Anticancer Platinum Compound by Inductively Coupled Plasma Mass Spectrometry after Intravenous Administration to Rats

Photosubstitution and photoreduction of a diazido platinum(IV) anticancer complex

Structural Studies of Dicycloplatin-an Antitumor Supramolecule

Determination Of Platinum In Serum And Tissues By Inductively Coupled Plasma-Atomic Emission Spectrometry

Analytical Methodologies for the Analysis of Platinum-containing Anticancer Drugs and its Interaction Mechanisms

THE SYNTHESIS AND CHARACTERIZATION OF DINUCLEAR PLATINUM COMPLEXES BRIDGED BY DIPYRIDYL SELENIDES OR SULFIDES

Synthesis, Characterization, and Cytotoxicity Evaluation of Novel Water‐Soluble Cationic Platinum(II) Organometallic Complexes with Phenanthroline and Imidazolic Ligands

Anticancer Effect of PtIIPHEN SS, PtII5ME SS, PtII56ME SS and Their Platinum(IV)-Dihydroxy Derivatives against Triple-Negative Breast Cancer and Cisplatin-Resistant Colorectal Cancer

Effective monitoring of Platinum-DNA adducts formation under simulated physiological conditions by CE-ICP-MS/MS

Improved method for quantification of intact oxaliplatin by ultra high performance liquid chromatography-inductively coupled plasma mass spectrometry: Applications to clinical and speciation studies

Development and Validation of an Inductively Coupled Plasma Mass Spectrometry (ICP-MS) Method for Quantitative Analysis of Platinum in Plasma, Urine, and Tissues

Effect of geometric isomerism on the anticancer property of new platinum complexes with glycine derivatives as asymmetric N, O donate ligands against human cancer

Noncovalent Interactions Between a Trinuclear Monofunctional Platinum Complex and Human Serum Albumin.

Pharmacokinetics and Tissue Distribution of Two Novel Isomerism Anticancer Platinum Compounds

ESMS and NMR investigations on the interaction of the anticancer drug cisplatin and chemopreventive agent selenomethionine †

Platinum and Palladium Polyamine Complexes as Anticancer Agents: The Structural Factor

Preconcentration and determination of ultra-traces of platinum in human serum using the combined electrodeposition-electrothermal atomic absorption spectroscopy (ED-ETAAS) and chemometric method

Pharmacokinetics and Tissue Distribution in Rats of a Novel Anticancer Platinum Compound LLC-1903